Edwards Lifesciences disclosed that its RESILIA tissue‑based aortic valve replacements achieved 97.9% freedom from structural valve deterioration, 97.8% freedom from reoperation, and 98.6% freedom from non‑structural valve dysfunction at 10 years in a prospective, multicenter study that enrolled more than 500,000 patients worldwide. The trial also confirmed stable hemodynamics and low gradients over the decade, underscoring the long‑term performance of the technology.
The results strengthen Edwards’ competitive moat in the aortic‑valve market, where the company holds roughly 55‑60% of the global share and 60‑65% in the United States. Demonstrating durability in a younger, higher‑risk cohort suggests that RESILIA tissue can support longer patient lifespans, a key differentiator that may translate into market‑share gains and support future growth in both surgical and transcatheter product lines.
CEO Bernard Zovighian said, “As patients live longer and expect to remain active, structural heart therapies must be designed with lifetime care in mind.” Dr. Lars G. Svensson of the Cleveland Clinic added, “These 10‑year data from the COMMENCE trial suggest this tissue technology has the potential to change the way we think about durability in biological valves, including in younger patients. What is striking is the low rate of structural valve deterioration and need for reoperation, even though the trial enrolled younger patients who historically face higher risks of valve deterioration, underscoring the importance of long‑term evidence when….”
The COMMENCE trial is a 10‑year, single‑arm, observational, FDA‑approved pivotal study. Earlier 7‑year data showed 99.3% freedom from structural valve deterioration and 97.2% freedom from reoperation, while 8‑year data highlighted a 99.3% versus 90.5% gap between RESILIA and non‑RESILIA tissue. RESILIA technology is incorporated into Edwards’ INSPIRIS RESILIA aortic valve, KONECT RESILIA aortic valved conduit, MITRIS RESILIA mitral valve, and SAPIEN 3 Ultra RESILIA transcatheter aortic heart valve.
The durability advantage positions Edwards to capture a larger share of the projected 8% CAGR TAVR market through 2034, while also reinforcing its surgical portfolio. By providing evidence that RESILIA valves can meet the longevity expectations of an aging but increasingly active patient population, the company is better positioned to influence physician and payer decisions, potentially translating into sustained revenue growth and a stronger competitive stance against rivals such as Medtronic.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.